The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction

An association has been shown between plasma renin activity (PRA) and the risk of cardiovascular disease. There is also evidence that angiotensin II exerts detrimental effects on progression and instabilization of atherosclerotic plaque. The renin-angiotensin system (RAS) can be inhibited through inhibition of angiotensin I (Ang I) generation from angiotensinogen by direct renin inhibitors, inhibition of angiotensin II (Ang II) generation from angiotensin I by angiotensin-converting enzyme inhibitors and finally by direct inhibition of the action of Ang II receptor level. Aliskiren, the first direct renin inhibitor to reach the market, is a low-molecular-weight, orally active, hydrophilic nonpeptide. Aliskiren blocks Ang I generation, while plasma renin concentration increases because the drugs blocks the negative feed-back exerted by Ang II on renin synthesis. Because of its long pharmacological half-life, aliskiren is suitable for once-daily administration. Its through-to-peak ratio approximates 98% for the 300 mg/day dose. Because of its mechanism of action, aliskiren might offer the additional opportunity to inhibit progression of atherosclerosis at tissue level. Hypertension is an approved indication for this drug, which is also promising for the treatment of heart failure. The efficacy of this drug in reducing major clinical events is being tested in large ongoing clinical trials.

[1]  E. Lewis,et al.  Aliskiren combined with losartan in type 2 diabetes and nephropathy. , 2008, The New England journal of medicine.

[2]  S. Solomon,et al.  Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure , 2008, Circulation. Heart failure.

[3]  D. Ganten,et al.  Update on tissue renin–angiotensin systems , 2008, Journal of Molecular Medicine.

[4]  S. Yusuf,et al.  Telmisartan, ramipril, or both in patients at high risk for vascular events. , 2008, The New England journal of medicine.

[5]  A. H. J. Danser,et al.  Prorenin anno 2008 , 2008, Journal of Molecular Medicine.

[6]  Y. Uresin,et al.  9.10 Aliskiren, a Novel Renin Inhibitor, Has Greater Blood Pressure Lowering Effect Than Ramipril and Additional Blood Pressure Lowering Effect When Combined with Ramipril in Patients with Diabetes and Hypertension , 2007 .

[7]  S. Vaidyanathan,et al.  Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers , 2007, Drug Metabolism and Disposition.

[8]  S. Oparil,et al.  Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial , 2007, The Lancet.

[9]  G. Mcinnes.  Renin inhibition: the holy grail of renin–angiotensin system blockade? , 2007, Journal of Human Hypertension.

[10]  J. Li,et al.  A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension , 2007, Journal of Human Hypertension.

[11]  J. Jordan,et al.  Direct Renin Inhibition With Aliskiren in Obese Patients With Arterial Hypertension , 2007, Hypertension.

[12]  B. Oh,et al.  Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. , 2007, Journal of the American College of Cardiology.

[13]  D. Calhoun,et al.  Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide , 2007, Journal of hypertension.

[14]  Roland E Schmieder,et al.  Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. , 2007, American journal of hypertension.

[15]  H. Itakura,et al.  Aliskiren, a Novel Oral Renin Inhibitor, Provides Dose-Dependent Efficacy and Placebo-Like Tolerability in Japanese Patients with Hypertension , 2006, Hypertension Research.

[16]  A. Danser,et al.  The (pro)renin receptor: therapeutic consequences , 2006, Expert opinion on investigational drugs.

[17]  E. Park,et al.  Binding properties of rat prorenin and renin to the recombinant rat renin/prorenin receptor prepared by a baculovirus expression system. , 2006, International journal of molecular medicine.

[18]  A. Nishiyama,et al.  Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. , 2006, Journal of the American Society of Nephrology : JASN.

[19]  G. Nguyen.  Renin/prorenin receptors. , 2006, Kidney international.

[20]  J. Ménard,et al.  Conformational changes in prorenin during renin inhibition in vitro and in vivo , 2006, Journal of hypertension.

[21]  Ling Yu,et al.  Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. , 2006, Kidney international.

[22]  J. A. Oliver,et al.  Receptor-mediated actions of renin and prorenin. , 2006, Kidney international.

[23]  W. Dieterle,et al.  Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. , 2005, International journal of clinical pharmacology and therapeutics.

[24]  M. Wellner,et al.  Aliskiren, a Human Renin Inhibitor, Ameliorates Cardiac and Renal Damage in Double-Transgenic Rats , 2005, Hypertension.

[25]  M. Woodward,et al.  Prediction of Myocardial Infarction by N-Terminal-Pro-B-Type Natriuretic Peptide, C-Reactive Protein, and Renin in Subjects With Cerebrovascular Disease , 2005, Circulation.

[26]  R. Schmieder,et al.  Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients , 2005, Circulation.

[27]  J. Ménard,et al.  Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats , 2005, Journal of hypertension.

[28]  Joël Ménard,et al.  Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. , 2004, Journal of the American Society of Nephrology : JASN.

[29]  W. Dieterle,et al.  Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. , 2004, British journal of clinical pharmacology.

[30]  J. Wilkinson-Berka.  Diabetes and retinal vascular disorders: role of the renin–angiotensin system , 2004, Expert Reviews in Molecular Medicine.

[31]  A. Stanton,et al.  Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren , 2003, Hypertension.

[32]  Alice Stanton,et al.  Structure-based design of aliskiren, a novel orally effective renin inhibitor. , 2003, Biochemical and biophysical research communications.

[33]  A. Turner.  Exploring the structure and function of zinc metallopeptidases: old enzymes and new discoveries. , 2003, Biochemical Society transactions.

[34]  D. Rader,et al.  Renin-angiotensin system and atherothrombotic disease: from genes to treatment. , 2003, Archives of internal medicine.

[35]  G. Nguyen,et al.  Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. , 2002, The Journal of clinical investigation.

[36]  G. Wuerzner,et al.  Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100): Comparison With Enalapril , 2002, Hypertension.

[37]  K. Schmidt-Ott,et al.  The multiple actions of angiotensin II in atherosclerosis , 2000, Regulatory Peptides.

[38]  K. Robison,et al.  A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9 , 2000, Circulation research.

[39]  J. Wood,et al.  Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. , 2000, Chemistry & biology.

[40]  N. Hollenberg,et al.  The paradox of the low-renin state in diabetic nephropathy. , 1999, Journal of the American Society of Nephrology : JASN.

[41]  S. Clausmeyer,et al.  An alternative transcript of the rat renin gene can result in a truncated prorenin that is transported into adrenal mitochondria. , 1999, Circulation research.

[42]  H. Hense,et al.  Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans , 1998, Journal of hypertension.

[43]  A. Danser,et al.  Mannose 6-phosphate receptor-mediated internalization and activation of prorenin by cardiac cells. , 1997, Hypertension.

[44]  J. Laragh,et al.  Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. , 1997, American journal of hypertension.

[45]  N. Seidah,et al.  Proteolytic processing of human prorenin in renal and non-renal tissues. , 1994, Kidney International.

[46]  A. Fukamizu,et al.  Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes. , 1993, The Journal of biological chemistry.

[47]  J. Sealey,et al.  Highest concentrations of prorenin and human chorionic gonadotropin in gestational sacs during early human pregnancy. , 1992, The Journal of clinical endocrinology and metabolism.

[48]  D. Ganten,et al.  Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Laragh,et al.  Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. , 1991, The New England journal of medicine.

[50]  J D Baxter,et al.  Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution. , 1989, Science.

[51]  P T de Jong,et al.  Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. , 1989, The Journal of clinical endocrinology and metabolism.

[52]  J. Laragh,et al.  Prorenin secretion from human testis: no evidence for secretion of active renin or angiotensinogen. , 1988, The Journal of clinical endocrinology and metabolism.

[53]  Schalekamp Ma,et al.  Human prorenin: pathophysiology and clinical implications. , 1988 .

[54]  M. Schalekamp,et al.  Human prorenin: pathophysiology and clinical implications. , 1988, Clinical and experimental hypertension. Part A, Theory and practice.

[55]  Z. Rosenwaks,et al.  Plasma prorenin response to human chorionic gonadotropin in ovarian-hyperstimulated women: correlation with the number of ovarian follicles and steroid hormone concentrations. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[56]  F. de Jong,et al.  Source of plasma prorenin in early and late pregnancy: observations in a patient with primary ovarian failure. , 1987, The Journal of clinical endocrinology and metabolism.

[57]  J. Wood,et al.  Inhibitors of renin as potential therapeutic agents. , 1987, Journal of enzyme inhibition.

[58]  M. James,et al.  Stereochemical analysis of peptide bond hydrolysis catalyzed by the aspartic proteinase penicillopepsin. , 1985, Biochemistry.

[59]  D. Wilson,et al.  Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. , 1985, The New England journal of medicine.

[60]  A. Slabý,et al.  [Plasma renin activity and ischemic heart disease]. , 1975, Casopis lekaru ceskych.

[61]  C. Johnston,et al.  Plasma Renin Levels and Vascular Complications in Hypertension , 1973, British medical journal.

[62]  J. Laragh,et al.  Essential hypertension: renin and aldosterone, heart attack and stroke. , 1972, The New England journal of medicine.

[63]  L. Skeggs,et al.  THE PREPARATION, PURIFICATION, AND AMINO ACID SEQUENCE OF A POLYPEPTIDE RENIN SUBSTRATE , 1957, The Journal of experimental medicine.

[64]  K. Bestehorn,et al.  Vascular Health and Risk Management , 2022 .